Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nivolumab for squamous-cell non-small-cell lung cancer.

× No keyword cloud information.

10 in total

1. Immunotherapy for lung cancer.

Authors: María González-Cao
Journal: Transl Lung Cancer Res Date: 2015-12

Review 2. Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors: Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal: Adv Drug Deliv Rev Date: 2015-12-11 Impact factor: 15.470

3. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors.

Authors: Yanping Wu; Lianjun Lin; Xinmin Liu
Journal: Dis Markers Date: 2020-06-09 Impact factor: 3.434

Review 4. Potential role of immunotherapy in advanced non-small-cell lung cancer.

Authors: Ramon Andrade de Mello; Ana Flávia Veloso; Paulo Esrom Catarina; Sara Nadine; Georgios Antoniou
Journal: Onco Targets Ther Date: 2016-12-16 Impact factor: 4.147

5. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.

Authors: ShengFa Su; YinXiang Hu; WeiWei Ouyang; Zhu Ma; QingSong Li; HuiQin Li; Yu Wang; XiaoHu Wang; Tao Li; JianCheng Li; Ming Chen; You Lu; YuJu Bai; ZhiXu He; Bing Lu
Journal: BMC Cancer Date: 2016-11-21 Impact factor: 4.430

6. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.

Authors: Nan Chen; Wenfeng Fang; Zhong Lin; Peijian Peng; Juan Wang; Jianhua Zhan; Shaodong Hong; Jiaxing Huang; Lin Liu; Jin Sheng; Ting Zhou; Ying Chen; Hongyu Zhang; Li Zhang
Journal: Cancer Immunol Immunother Date: 2017-04-27 Impact factor: 6.968

7. PD-1 regulates KLRG1⁺ group 2 innate lymphoid cells.

Authors: Samuel Taylor; Yuefeng Huang; Grace Mallett; Chaido Stathopoulou; Tania C Felizardo; Ming-An Sun; Evelyn L Martin; Nathaniel Zhu; Emma L Woodward; Martina S Elias; Jonathan Scott; Nick J Reynolds; William E Paul; Daniel H Fowler; Shoba Amarnath
Journal: J Exp Med Date: 2017-05-10 Impact factor: 14.307

Review 8. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

Authors: Liting Guo; Haijun Zhang; Baoan Chen
Journal: J Cancer Date: 2017-02-10 Impact factor: 4.207

9. Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review.

Authors: Zhe Zhang; Yishan Chen; Mingxia Ma; Junli Hao; Rui Ding; Lixin Han; Jiayun Zou; Lina Zhang; Qin Meng; Xiujuan Qu; Yunpeng Liu; Mingfang Zhao
Journal: Oncotarget Date: 2017-07-07

10. PD-1 blockade restores impaired function of ex vivo expanded CD8⁺ T cells and enhances apoptosis in mismatch repair deficient EpCAM⁺PD-L1⁺ cancer cells.

Authors: Rajeev Kumar; Fang Yu; Yuan-Huan Zhen; Bo Li; Jun Wang; Yuan Yang; Hui-Xin Ge; Ping-Sheng Hu; Jin Xiu
Journal: Onco Targets Ther Date: 2017-07-13 Impact factor: 4.147

10 in total